Concessions in renegotiated NAFTA will lead to ‘extra cost’ for Canadians and a potential pharmacare plan, but an expert says it could’ve been worse

A generic drug industry association head says concessions in free trade pacts have been 'death by a thousand cuts' for the industry.

U.S President Donald J. Trump, middle, with then-Mexican President Enrique Pena Nieto, left, and Canadian Prime Minister Justin Trudeau, right, at the USMCA signing ceremony on Nov. 30, 2018, in Buenos Aires, Argentina. The renegotiated trade pact increases protection on biologics from eight to 10 years.Photo by Shealah Craighead/White House

News

BY NEIL MOSS

February 4, 2019

Increased protection of innovative drugs will lead to an added cost for Canadians, but the trade concession doesn't infringe on Canada's ability to implement a national pharmacare plan, says an industry expert. Since the United States-Mexico-Canada Agreement (USMCA) was drafted at the end of Septem...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Today’s Headlines Newsletter

Your quick scan of the news you need each weekday to be the smartest person in the room.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy